Answer
The most frequently reported side effects in four 68-week phase 3a trials involving 2,650 adults receiving Wegovy (semaglutide) 2.4 mg were gastrointestinal disorders, including nausea, diarrhoea, constipation and vomiting.
Sources for this answer
- Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled penNovo Nordisk Limited · emc · SmPC §4.8 Undesirable effects · Version 16Document updated
Sources checked